1-METHYL-4-(TRIFLUOROMETHYL)-1H-PYRAZOLE-3-CARBOXYLIC ACID, 95%, 250mg

4-ethylpiperidine, 95.0%, 5g

6-Bromo-4-nitropicolinic acid, 97%, 100mg

(E)-METHYL 3-(3-(((4'-(DIMETHYLAMINO)-[1,1'-BIPHENYL]-4-YL)METHYL)AMINO)PHENYL)ACRYLATE, 90.0%, 250mg

4-(trifluoromethyl)-1,2-dihydropyridine-2-thione, 98%, 1g

2,4-Dibromo-1-(trifluoromethoxy)benzene, 98%, 250mg

(3-(tert-Butylcarbamoyl)-4-chlorophenyl)boronic acid, 95.0%, 1g

TERT-BUTYL 2-(2-METHOXY-2-OXOETHYL)PIPERAZINE-1-CARBOXYLATE, 95%, 5g

Plan phase PLPHi 20x/0.40 infinity corrected IOS objective. Working distance 8.80 mm

3-Benzyloxazolidine>98.0%(GC)(T)1g

5-METHOXYCHROMAN-3-CARBOXYLIC ACID, 97.0%, 100mg

5-Bromo-1H-thieno[2,3-c]pyrazole, 98%, 100mg

3-Boc-Amino-3-(3'-chlorophenyl)propionic acid, 95.0%, 25g